This Newly Approved Narcolepsy Drug Is the First to Target the Sleep Disorder's Root Cause Rather Than Its Symptoms
/https://tf-cmsv2-smithsonianmag-media.s3.amazonaws.com/filer_public/47/fc/47fc814d-c7fd-46ae-b4d2-5f8be614e012/narcolepsy.jpg)
In early August, the Food and Drug Administration (FDA) approved the first drug that targets the root cause of a form of narcolepsy, a chronic brain disorder that causes extreme daytime sleepiness. The twice-daily oral drug, marketed as Orzeyful, could be a boon for the roughly 120,000 people in the United States with narcolepsy type 1.
Reported by 1 outlet — Smithsonian. See all sources ↓
In early August, the Food and Drug Administration (FDA) approved the first drug that targets the root cause of a form of narcolepsy, a chronic brain disorder that causes extreme daytime sleepiness. The twice-daily oral drug, marketed as Orzeyful, could be a boon for the roughly 120,000 people in the United States with narcolepsy type 1. The disease is linked to the death of brain cells that produce orexin, a chemical that plays roles in wakefulness, sleep and muscle tone. The loss leads to excessive daytime sleepiness, sleep paralysis, hallucinations when falling asleep and waking up, disrupted nighttime sleep and cataplexy—sudden muscle weakness while fully awake.
Read the full report at Smithsonian ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- In early August, the Food and Drug Administration (FDA) approved the first drug that targets the root cause of a form of narcolepsy, a chronic brain disorder that causes extreme daytime sleepiness. The twice-daily oral drug, marketed as Orzeyful, could be a boon for the roughly 120,000 people in the United States with narcolepsy type 1.
- How widely is it covered?
- 1 outlet, average source rating 7.0/10.
- When was it last updated?
- 4m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
This Newly Approved Narcolepsy Drug Is the First to Target the Sleep Disorder's Root Cause Rather Than Its Symptoms
Sources1TypeCoverageSmithsonian